Skip to main content

Unable to load price data. Sorry.

¯\_(ツ)_/¯

Trius Therapeutics, Inc. (NASDAQ:TSRX.DL)

CAPS Rating: No stars

Unable to load market data for this Ticker. Sorry.

¯\_(ツ)_/¯

Caps

This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

0 Outperform
0 Underperform
 

All-Star Players

0 Outperform
0 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:TSRX.DL Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

smolinaroli (< 20)
Submitted August 22, 2011

The bullet is.1)Lead drug in Phase 3 is an improved version of the market leading antibiotic to fight resistant staph infections. Phase 3 data expected early 2012. Two trials underway both received FDA SPA. Which is basically a fast track for… More

zzlangerhans (98.68)
Submitted May 14, 2011

Trius's share price has now more than doubled from the December lows without a true positive catalyst. The only thing that's new is a very positive write up from Zacks. They make some good points, but I haven't found Zacks to be a very strong… More

NASDAQ:TSRX.DL VS S&P 500 (SPY)

NASDAQ:TSRX.DL Summary

  • Sector:
  • Industry:
  • Tags:

Recent Community Commentary

Read the most recent pitches from players about TSRX.DL.

No one has written a Pitch for TSRX.DL stock yet. Tell us why you think TSRX.DL will outperform or underperform against the market.

Leaderboard

Find the members with the highest scoring picks in TSRX.DL.

No players have picked TSRX.DL yet. Tell us why you think TSRX.DL will outperform or underperform against the market.

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for TSRX.DL.